Patient Square Capital LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001819257
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 24 positions · Total reported value $373.86M · Top-10 concentration 85.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 69.0% · 6 new · 8 cut · 6 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q3 2025 13F filing, Patient Square Capital LP disclosed 24 equity positions with a combined reported value of $373.86M. The filing implies a focused portfolio: its ten largest positions account for 85.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were ROIV ($188.82M), INSM ($47.00M), EYPT ($14.41M). By sector, the heaviest allocations are Health Care 93.0%, Industrials 3.9%. Versus the prior quarter, allocation shifted toward Other (+2.6pp) and away from Industrials (-0.7pp), Health Care (-1.9pp).
Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 59% of names.
The largest new positions opened in Q3 2025 were ABVX ($12.89M), CELC ($4.94M), DNTH ($4.92M).
Of the 6 positions fully exited versus the prior quarter, the largest were CGEM ($6.54M), SRRK ($5.45M), VYNE ($523.10K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- ABVX ABIVAX SA · $12.89M
- CELC CELCUITY INC · $4.94M
- DNTH DIANTHUS THERAPEUTICS INC · $4.92M
- QURE UNIQURE NV · $4.38M
- AMLX AMYLYX PHARMACEUTICALS INC · $4.30M
- ASMB ASSEMBLY BIOSCIENCES INC · $3.46M
- AVTX AVALO THERAPEUTICS INC · $1.27M
- CATX PERSPECTIVE THERAPEUTICS INC · $1.20M
Insider Transactions (Form 4)
Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.
Investment Approach
They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.
Asset Classes
Primarily invests in US equities, as evidenced by their SEC Form 13F filings.
Notable Facts
Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.
Key People
Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).
For official disclosures, refer to the firm's SEC filings.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
12.48M | $188.82M | 50.51% | Hold | |
| 2 |
|
326.40K | $47.00M | 12.57% | Reduce | |
| 3 |
|
1.01M | $14.41M | 3.85% | Reduce | |
| 4 |
|
151.83K | $12.89M | 3.45% | New | |
| 5 |
|
121.00K | $11.59M | 3.10% | Add | |
| 6 |
|
15.50K | $11.43M | 3.06% | Reduce | |
| 7 |
|
400.00K | $9.10M | 2.43% | Reduce | |
| 8 |
|
345.38K | $8.62M | 2.31% | Add | |
| 9 |
|
715.00K | $8.36M | 2.24% | Reduce | |
| 10 |
|
104.26K | $7.64M | 2.04% | Reduce | |
| 11 |
|
133.83K | $5.37M | 1.44% | Reduce | |
| 12 |
|
92.59K | $5.24M | 1.40% | Reduce | |
| 13 |
|
250.84K | $5.13M | 1.37% | Add | |
| 14 |
|
100.00K | $4.94M | 1.32% | New | |
| 15 |
|
125.00K | $4.92M | 1.32% | New | |
| 16 |
|
74.00K | $4.89M | 1.31% | Hold | |
| 17 |
|
75.00K | $4.38M | 1.17% | New | |
| 18 |
|
316.31K | $4.30M | 1.15% | New | |
| 19 |
|
437.24K | $4.04M | 1.08% | Add | |
| 20 |
|
2.98M | $3.70M | 0.99% | Add | |
| 21 |
|
135.18K | $3.46M | 0.93% | New | |
| 22 |
|
100.00K | $1.27M | 0.34% | New | |
| 23 |
|
349.32K | $1.20M | 0.32% | New | |
| 24 |
|
845.00K | $1.16M | 0.31% | Add | |
FAQ
What did Patient Square Capital LP buy in 2025-Q3?
In its 2025-Q3 13F filing, Patient Square Capital LP reported 24 equity positions worth $373.86M in aggregate; its largest disclosed positions were ROIV ($188.82M), INSM ($47.00M), EYPT ($14.41M).
How large is Patient Square Capital LP's portfolio?
Patient Square Capital LP reported $373.86M of long equity holdings across 24 positions as of 2025-Q3. Top-10 holdings account for 85.6% of reported value.
What is Patient Square Capital LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.